BAY 1179470

Drug Profile

BAY 1179470

Alternative Names: BAY-1179470; FGFR-moAb

Latest Information Update: 06 Sep 2016

Price : $50

At a glance

  • Originator Bayer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Aug 2016 Bayer completes a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in Japan, Singapore and South Korea (NCT01881217)
  • 21 Oct 2015 Phase-I development for Solid tumours (Late-stage disease, Second-line therapy or greater) is ongoing in Japan, South Korea and Singapore (NCT01881217)
  • 16 Dec 2014 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in South Korea and Singapore (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top